Companies
Who we bring together sets us apart
Companies
Our tenants span the life science sector, including therapeutics, diagnostics, medical devices, and research tools. They learn from and support each other, often forming partnerships.
Press Release
ARIZ and NATA Announce Collaboration to develop multiple targeted nucleic acid therapies for cancer treatment
ARIZ and NATA have announced an exciting new partnership aimed at advancing cancer treatment through the development of multiple targeted nucleic acid therapies. By combining ARIZ’s cutting-edge research and NATA’s expertise in molecular medicine, the collaboration seeks to pave the way for innovative therapies that could revolutionize the way cancer is treated. This strategic alliance marks a significant step forward in the fight against cancer, offering new hope for more personalized and effective treatments. Read post
Press Release
Seaweed Innovators Sway and Umaro Join Forces to Optimize Alginate for Sustainable Bioplastics
Bay Area-based seaweed innovation startups Umaro and Sway have been awarded a Department of Energy (DOE) Mixed Algae Conversion Research Opportunity (MACRO) grant of $1,500,000 to innovate new processing techniques that upcycle alginate sidestreams from Umaro’s seaweed protein production into Sway’s seaweed-based bioplastics. Read post
Tenant Spotlight
Tenant Spotlight on ARIZ: Rising to the Challenge to Make Cancer Treatments More Humane
Cancer treatments are often as grueling as the disease itself—chemotherapy can bring unbearable side effects like debilitating fatigue, nausea, and hair loss, leaving patients vulnerable and stripped of their identity. But what if cancer care could be better? More precise? Less harmful? Enter ARIZ Precision Medicine. Their mission is to revolutionize cancer care by developing therapies that not only fight the disease but also preserve the quality of life for patients. Learn how they’re doing this in our latest Tenant Spotlight. Read post
Company News
ARIZ One of “Eight Nanotechnology Companies to Watch Out for”
The company’s product is composed of a nanoparticle, which is customized based on the kind of cancer it is attacking, and has small interfering RNA (siRNA) that kill proteins that drive cancer without harming the neighboring healthy cells, cancer cell targeting peptides, as well as the chemotherapy drug – which is encapsulated within the nanoparticle. The nanoparticle is PEGylated, a process by which the polymer polyethylene glycol (PEG) is added to protect the drug. Read post
Company News
Berkeley startup wins government award to develop radiation and lead poisoning treatment
Bakar Labs tenant company HOPO Therapeutics was recently featured in The Los Angeles Times for their technology that can save millions of lives with a single pill. Read post
Press Release
Biocom California Names the Ninth Annual Life Science Catalyst Award Winners
Sophia Lugo, CEO and co-founder of Bakar Labs tenant company Radar Therapeutics, has been selected as one of the recipients of the award. The Catalyst Award recognizes 10 life science trailblazers under the age of 40 across California. Read post
Company News
HOPO Therapeutics wins up to $226M BARDA contract for heavy metal poisoning research
Endpoints News covered HOPO Therapeutics’ recent accomplishment of securing a $226 million contract with BARDA. Read post
Press Release
HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity
The funds will be used to advance development of the drug candidate HOPO-101 through registrational studies as a medical countermeasure against radiological threats, including planned submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). The initial award of approximately $9.4 million will fund toxicology and pharmacology studies, manufacturing activities, and nonclinical research in other types of heavy metal poisoning, with approximately $216 million in additional funding available for later-stage development upon agreement between BARDA and HOPO. Read post